Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/58942
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
Metadatos
Mostrar el registro completo del ítem
BRIDGING THE IMMUNOGENICITY OF A TETRAVALENT DENGUE VACCINE (TAK-003) FROM CHILDREN AND ADOLESCENTS TO ADULTS
Vacina tetravalente
Dengue (TAK-003)
Crianças
Adolescentes
Adultos
Tetravalent vaccine
Dengue (TAK-003)
Children
Adolescents
Adults
Autor
Afiliación
Vaccines Business Unit. Takeda Pharmaceuticals International AG. Zürich, Switzerland.
University of the Philippines. College of Medicine. Manila, Philippines.
Vaccines Business Unit. Takeda Pharmaceuticals International AG. Zürich, Switzerland.
Universidad Del Valle. Centro de Estudios en Infectología Pediatrica CEIP. Department of Pediatrics. Clínica Imbanaco. Grupo Quironsalud. Cali, Colombia.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Associação Obras Sociais Irmã Dulce Hospital Santo Antônio. Salvador, BA, Brasil.
Takeda Vaccines Inc. Cambridge, MA, USA.
Takeda Vaccines Inc. Cambridge, MA, USA.
The Division of Environmental and Occupational Health Sciences. University of Illinois at Chicago School of Public Health. Chicago, IL, USA.
Vaccines Business Unit. Takeda Pharmaceuticals International AG. Zürich, Switzerland.
Department of Pediatrics. Phramongkutklao Hospital and Faculty of Medicine. Kasetsart University. Bangkok, Thailand.
Anaheim Clinical Trials. Anaheim, CA, USA.
Takeda Vaccines Inc. Cambridge, MA, USA.
University of the Philippines. College of Medicine. Manila, Philippines.
Vaccines Business Unit. Takeda Pharmaceuticals International AG. Zürich, Switzerland.
Universidad Del Valle. Centro de Estudios en Infectología Pediatrica CEIP. Department of Pediatrics. Clínica Imbanaco. Grupo Quironsalud. Cali, Colombia.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Associação Obras Sociais Irmã Dulce Hospital Santo Antônio. Salvador, BA, Brasil.
Takeda Vaccines Inc. Cambridge, MA, USA.
Takeda Vaccines Inc. Cambridge, MA, USA.
The Division of Environmental and Occupational Health Sciences. University of Illinois at Chicago School of Public Health. Chicago, IL, USA.
Vaccines Business Unit. Takeda Pharmaceuticals International AG. Zürich, Switzerland.
Department of Pediatrics. Phramongkutklao Hospital and Faculty of Medicine. Kasetsart University. Bangkok, Thailand.
Anaheim Clinical Trials. Anaheim, CA, USA.
Takeda Vaccines Inc. Cambridge, MA, USA.
Resumen en ingles
Immunobridging is an important methodology that can be used to extrapolate vaccine efficacy estimates to populations not evaluated in clinical studies, and that has been successfully used in developing many vaccines. Dengue, caused by a mosquito-transmitted flavivirus endemic to many tropical and subtropical regions, is traditionally thought of as a pediatric disease but is now a global threat to both children and adults. We bridged immunogenicity data from a phase 3 efficacy study of a tetravalent dengue vaccine (TAK-003), performed in children and adolescents living in endemic areas, with an immunogenicity study in adults in non-endemic areas. Neutralizing antibody responses were comparable in both studies following receipt of a two-dose TAK-003 schedule (months 0 and 3). Similar immune responses were observed across exploratory assessments of additional humoral responses. These data support the potential for clinical efficacy of TAK-003 in adults.
Palabras clave en portugues
ImunogenicidadeVacina tetravalente
Dengue (TAK-003)
Crianças
Adolescentes
Adultos
Palabras clave en ingles
ImmunogenicityTetravalent vaccine
Dengue (TAK-003)
Children
Adolescents
Adults
Compartir